Annual Drug Patent Expirations for MEGACE+ES
Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for MEGACE ES.
This drug has one hundred and eigthy-eight patent family members in twenty-eight countries.
The generic ingredient in MEGACE ES is megestrol acetate. One supplier is listed for this compound. Additional details are available on the megestrol acetate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
